Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

2(33%)

Results Posted

50%(2 trials)

Phase Distribution

Ph phase_1

33%

Ph phase_3

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

2(33.3%)

Phase 3Large-scale testing

4(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(4)

Detailed Status

Completed4

Recruiting1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (33.3%)

Phase 34 (66.7%)

Trials by Status

completed467%

recruiting117%

active_not_recruiting117%

Recent Activity

2 active trials

Showing 5 of 6

active_not_recruitingphase_3

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257

recruitingphase_3

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

NCT05422222

completedphase_3

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

NCT05033080

completedphase_3

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

NCT05076149

completedphase_1

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

NCT05437120

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT05444257Phase 3

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Active Not Recruiting

NCT05422222Phase 3

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Recruiting

NCT05033080Phase 3

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Completed

NCT05076149Phase 3

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Completed

NCT05437120Phase 1

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Completed

NCT05535959Phase 1

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6